Drugs / nab-sirolimus
Trials 12
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT06308419 | Aug 2024 → Feb 2029 expected | leiomyosarcoma | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05661461 | Nov 2022 → Jun 2026 overdue | neoplasm | Aadi Bioscience, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT02975882 | Aug 2017 → Mar 2022 | central nervous system cancer, childhood neoplasm, refractory malignant neoplasm, secondary malignant neoplasm | Children's Oncology Group | Completed | No outcome recorded |
| Phase 1 | NCT02587325 | Apr 2017 → Aug 2022 | pulmonary hypertension | Aadi Bioscience, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03439462 | Jul 2018 → Aug 2022 | colorectal cancer | Aadi Bioscience, Inc. | Completed | No outcome recorded |
| Phase 27 trials | ||||||
| Phase 2 | NCT07104331 | Feb 2026 → Aug 2029 expected | epithelioid hemangioendothelioma | Sarcoma Alliance for Research through Collaboration | Recruiting | No outcome recorded |
| Phase 2 | NCT06494150 | Dec 2024 → Aug 2027 expected | ovarian serous adenocarcinoma | University of Oklahoma | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05997017 | Dec 2023 → Dec 2026 expected | endometrial carcinoma, endometrioid tumor | Aadi Bioscience, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT05997056 | Nov 2023 → May 2025 overdue | lung neuroendocrine neoplasm, pancreatic neuroendocrine tumor | Aadi Bioscience, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT05103358 | Mar 2022 → Dec 2024 | metastatic malignant neoplasm, tuberous sclerosis 1, tuberous sclerosis 2 | Aadi Bioscience, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03463265 | Aug 2018 → Aug 2022 | glioblastoma | Aadi Bioscience, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02494570 | Oct 2015 → Nov 2021 | neoplasm with perivascular epithelioid cell differentiation | Aadi Bioscience, Inc. | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | nab-sirolimus | “Nab-sirolimus (ABI-009, nab-rapamycin; Aadi Bioscience Inc. [Aadi]) is a human albumin-bound form of sirolimus nanoparticles, a potent mTOR inhibitor.” PMID 39487711 ↗ Nov 2024 |
| Known as | ABI-009 | “A phase 2, open-label study of nab-sirolimus (also known as ABI-009, nab-rapamycin, albumin-bound rapamycin) in patients with recurrent high grade glioma following prior...” NCT03463265 ↗1“nab-sirolimus (also known as ABI-009, nab-rapamycin, albumin-bound rapamycin)” NCT03439462 ↗ |
| Known as | albumin-bound rapamycin | “A phase 2, open-label study of nab-sirolimus (also known as ABI-009, nab-rapamycin, albumin-bound rapamycin) in patients with recurrent high grade glioma following prior...” NCT03463265 ↗1“nab-sirolimus (also known as ABI-009, nab-rapamycin, albumin-bound rapamycin)” NCT03439462 ↗ |
| Known as | nab-rapamycin | “A phase 2, open-label study of nab-sirolimus (also known as ABI-009, nab-rapamycin, albumin-bound rapamycin) in patients with recurrent high grade glioma following prior...” NCT03463265 ↗1“nab-sirolimus (also known as ABI-009, nab-rapamycin, albumin-bound rapamycin)” NCT03439462 ↗ |
| Action | Inhibit | “investigating the safety and efficacy of the mammalian target of rapamycin inhibitor nab-sirolimus (AMPECT, NCT02494570).” PMID 34637337 ↗ Oct 2021 |
| Route | Intravenous | “Patients received nab-sirolimus at 100 mg/m2 on Days 1 and 8 of a 21-day cycle by intravenous infusion over 30 minutes.” NCT02494570 ↗ |
| Target | MTOR | “Nab-sirolimus (ABI-009, nab-rapamycin; Aadi Bioscience Inc. [Aadi]) is a human albumin-bound form of sirolimus nanoparticles, a potent mTOR inhibitor.” PMID 39487711 ↗ Nov 2024 |